People who are suffering from cystic fibrosis have some great news from the Food and Drug Administration of the United States. The FDA has approved the general use of a new drug called Trikaftfa, which has been proven to be quite effective in curing cystic fibrosis. After so much testing and other procedure, FDA offered the approval for the drug and it can now be used for patients who are 12 or older. Also, it’s one of the very first drugs in the category to be approved for such a wider targeted group.
“In the past few years, we have seen remarkable breakthroughs in therapies to treat cystic fibrosis and improve patients’ quality of life, yet many subgroups of cystic fibrosis patients did not have approved treatment options. Today’s landmark approval is a testament to these efforts, making a novel treatment available to most cystic fibrosis patients, including adolescents, who previously had no options and giving others in the cystic fibrosis community access to additional effective therapy,” said Ned Sharpless in an official statement from the FDA. It should be noted that the drug is a breakthrough in the category as well as the group for whom it is prescribed.
As said earlier, cystic fibrosis is one of the most dangerous diseases in the world and it can affect different parts of the body. Digestive and respiratory issues are caused by the mucus that is created by the disease in addition to the common side effects and other symptoms. Since the very start of the drug, it has been a subject of thorough inspection and other clinical trials. In most of the trials, the drug was found to have an amazing impact on the patient. It’s the same reason why the general availability of the drug brings a lot of hope to people who are troubled by the condition.
Jamie is the senior news reporter for News Fior and covers Health. Prior to working for News Fior, she worked for the Daily Mail. She has also worked as a reporter and blogger at the Lexington Herald-Leader in Kentucky. Her Twitter profile reads Michigander by birth, Georgian by curiosity.